2024
Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2023
Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger study
2022
COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey
Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.Peer-Reviewed Original ResearchCOVID-19 vaccine hesitancyVaccine hesitancySevere COVID-19 diseaseMean timeSample of PWHCells/mm3COVID-19 historyVaccine-related concernsGreater vaccine hesitancyCOVID-19 vaccineCOVID-19COVID-19 diseaseLower vaccine hesitancyCross-sectional online surveyCD4 countAssociated FactorsSide effectsHIVKey populationsPWHMultivariate linear regressionVaccineCOVID-19 epidemicHesitancyMost participants
2020
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disorders
2019
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testingUsing nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support
Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal Of Substance Use And Addiction Treatment 2019, 100: 18-28. PMID: 30898324, PMCID: PMC6432946, DOI: 10.1016/j.jsat.2019.01.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderNominal group techniquePharmacologic therapyUse disordersSyringe exchange programsIndividual-level barriersEvidence-based interventionsAddiction treatment centersEvidence-based strategiesOUD treatmentPharmacologic treatmentSpecific medicationsTreatment optionsPharmacologic propertiesMedicationsDecision aidPatient considerationsSide effectsTreatment centersOpioid crisisSpecific knowledge gapsGroup techniqueDecision aid developmentTreatmentTherapy
2017
Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populations
2015
“Bureaucracy & Beliefs”: Assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine
Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, Altice FL. “Bureaucracy & Beliefs”: Assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs Education Prevention And Policy 2015, 22: 255-262. PMID: 27087758, PMCID: PMC4831711, DOI: 10.3109/09687637.2015.1016397.Peer-Reviewed Original ResearchOpioid substitution therapySubstitution therapySide effectsEvidence-based HIV prevention strategiesOpioid-dependent PWIDHIV prevention strategiesMulti-level barriersImplementation science projectHIV preventionMethadone clientsTreatment accessWaiting listPWIDPrevention strategiesTreatment attitudesSocial marketing campaignFree treatmentTreatment slotsTreatmentPublic healthTherapyFocus group discussionsDrugsStructural barriersParticipants
2013
Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug And Alcohol Dependence 2013, 132: 378-382. PMID: 23414931, PMCID: PMC3718876, DOI: 10.1016/j.drugalcdep.2013.01.005.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentMethadone doseKaplan-Meier survival analysisDose escalation procedureMethadone initiationThirty HIVMMT clinicsEvaluable participantsMaintenance treatmentOpioid dependenceMMT programSide effectsHigh dosesSurvival analysisHIVFirst weekPilot studyDoseMonthsTreatmentEscalation procedureDosesCravingParticipantsMonths of release
2010
Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model
Simon MD, Altice FL, Moll AP, Shange M, Friedland GH. Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model. AIDS Care 2010, 22: 462-474. PMID: 20204909, DOI: 10.1080/09540120903220253.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy rolloutAntiretroviral therapy rolloutHIV/AIDSHAART rolloutHAART outcomesFolk remediesHIV treatment optimismMedication-taking behaviorOverall correct scoreBetter treatment outcomesResource-limited settingsBehavioral skills modelCommunity-based assessmentHAART initiationHIV optimismHIV testingHIV serostatusTreatment optimismTreatment outcomesSide effectsRural South AfricaCondom useHAARTTugela FerryYoung adults
2001
Trust and the Acceptance of and Adherence to Antiretroviral Therapy.
Altice FL, Mostashari F, Friedland GH. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47. PMID: 11579277, DOI: 10.1097/00042560-200109010-00008.Peer-Reviewed Original ResearchConceptsInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agentsTrust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice F, Mostashari F, Friedland G. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47-58. DOI: 10.1097/00126334-200109010-00008.Peer-Reviewed Original ResearchInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agents